Pharmaceutical Technology· GlobalData Healthcare·· 2 天前AI 评分22
ESMO26：Bayer 的 Nubeqa III 期告捷，生存获益与阿比特龙联用问题仍待解
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
AI 导读
Bayer 在 ESMO26 上公布 Nubeqa III 期研究取得阳性结果，但总生存获益及与阿比特龙联用的相关问题仍未明确。
正文 · 原文
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here
Powered by
来源：Pharmaceutical Technology · pharmaceutical-technology.com